Search results
Results From The WOW.Com Content Network
These genetically modified plants with Bt protein are grown on a large scale around the world. [2] Monsanto's corn line MON 810 is produced by ballistically transforming another corn line with a plasmid, PV-ZMCT10. [3] This plasmid has a cauliflower mosaic virus 35S promoter and hsp70 maize intron sequences which drive the expression of the ...
MON 802 is an Insect Resistant maize under license from Monsanto Company. [2] Corn line MON802 was developed through genetic modification to be tolerant [3] to glyphosate herbicide and protect the plant from the European corn borer (Ostrinia nubilalis) (the Bt trait). [4] MON 809 is an Insect Resistant maize under license from Monsanto. [5]
A 2002 review of the scientific literature concluded that "the commercial large-scale cultivation of current Bt–maize hybrids did not pose a significant risk to the monarch population". [ 81 ] [ 82 ] [ 83 ] A 2007 review found that "nontarget invertebrates are generally more abundant in Bt cotton and Bt maize fields than in nontransgenic ...
For premium support please call: 800-290-4726 more ways to reach us
In 1995 Monsanto's potato plants producing Bt toxin were approved by the Environmental Protection Agency, following approval by the FDA, making it the first pesticide-producing crop to be approved in the United States. [128] Monsanto subsequently developed Bt maize (MON 802, MON 809, MON 863, MON 810), Bt soybean [129] and Bt cotton.
North Maize Road is always a construction zone these days. As development has stretched north from 21st Street over the last several years, it seems like a new business or office or restaurant is ...
A U.S. Federal Trade Commission official said on Wednesday that the country's leading seafood restaurant chains have been warned that the agency will crack down on false claims of locally caught ...
In 2004, Monsanto sought approval in Europe to introduce MON 863. Approval was granted in 2005 for use in feed [5] and in 2006 for use in food. [6] There was controversy over acceptance by regulatory bodies of industry-funded toxicity studies and over the design of those studies led by Pr Gilles-Éric Séralini, who was on the committee that reviewed MON863 for the French government.